A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). (AcceleRET-MTC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04760288

Recruitment Status : Withdrawn (Due to several logistical challenges during start-up which could not be overcome study was withdrawn.)

First Posted : February 18, 2021

Last Update Posted : January 5, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Hoffmann-La Roche

No Study Results Posted on ClinicalTrials.gov for this Study

Study was withdrawn before participants were enrolled.

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Withdrawn
Estimated Primary Completion Date :	October 6, 2027
Estimated Study Completion Date :	April 12, 2035

To Top